NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
182 trialsNCT04133636 2026-03-17
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04404283 2026-03-17
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT05438043 2026-03-16
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07095452 2026-03-16
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT03901963 2026-03-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04722146 2026-03-13
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06768489 2026-03-13
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05552222 2026-03-12
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03984097 2026-03-10
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Active not recruiting
NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06149286 2026-03-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT04623541 2026-03-04
EPCOREâ„¢ CLL-1
Genmab
Phase 1/2 Active not recruiting
NCT05623020 2026-03-04
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT04542824 2026-03-03
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05660967 2026-03-03
EPCORE DLBCL-3
Genmab
Phase 2 Active not recruiting
NCT05950165 2026-03-03
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Cho Pharma Inc.
Phase 1/2 Recruiting
NCT06084936 2026-03-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06191744 2026-03-03
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06508658 2026-03-03
EPCORE DLBCL-4
Genmab
Phase 3 Recruiting
NCT04224493 2026-03-02
SYMPHONY-1
Ipsen
Phase 3 Recruiting
NCT05090566 2026-02-23
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Active not recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT04246086 2026-02-20
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05888493 2026-02-20
LEDA
Novartis
Phase 3 Active not recruiting
NCT06892522 2026-02-17
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Phase 1/2 Recruiting
NCT04712097 2026-02-04
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04669171 2026-01-30
SIDNEY
Enterome
Phase 1/2 Recruiting
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT04903197 2026-01-22
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
Phase 1 Terminated
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05222555 2026-01-16
MINDway
Incyte Corporation
Phase 1/2 Active not recruiting
NCT06679101 2026-01-08
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT05317416 2025-12-22
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
NCT05259839 2025-12-19
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
Phase 1 Active not recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT04661007 2025-12-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT07189065 2025-12-16
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Recruiting